Literature DB >> 9660991

Antifungal susceptibilities of Paecilomyces species.

C Aguilar1, I Pujol, J Sala, J Guarro.   

Abstract

The MICs and minimum fungicidal concentrations (MFCs) of amphotericin B, miconazole, itraconazole, ketoconazole, fluconazole, and flucytosine for 52 isolates of Paecilomyces species were evaluated by the broth microdilution method, largely based on the recommendations of the National Committee for Clinical Laboratory Standards (document M27-A). The fungal isolates tested included 16 P. variotii, 11 P. lilacinus, 9 P. marquandii, 6 P. fumosoroseus, 4 P. javanicus, and 2 P. viridis isolates and 1 isolate of each of the following species: P. carneus, P. farinosus, P. fulvus, and P. niveus. The MFCs and the MICs at which 90% of isolates were inhibited (MIC90s) for the six antifungal agents were remarkably high; the MIC50s indicated that amphotericin B, miconazole, itraconazole, and ketoconazole had good activities, while fluconazole and flucytosine demonstrated poor efficacy. The ranges of the MICs were generally wider and lower than those of the MFCs. There were significant susceptibility differences among the species. All species with the exception of P. variotii were highly resistant to fluconazole and flucytosine; P. variotii was susceptible to flucytosine. Amphotericin B and the rest of the azoles showed good activity against P. variotii, while all the antifungal agents assayed showed low efficacy against P. lilacinus.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9660991      PMCID: PMC105653     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  36 in total

1.  Collaborative comparison of broth macrodilution and microdilution antifungal susceptibility tests.

Authors:  A Espinel-Ingroff; C W Kish; T M Kerkering; R A Fromtling; K Bartizal; J N Galgiani; K Villareal; M A Pfaller; T Gerarden; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1992-12       Impact factor: 5.948

2.  Hyalohyphomycosis caused by Paecilomyces variotii: a case report, animal pathogenicity and 'in vitro' sensitivity.

Authors:  J Naidu; S M Singh
Journal:  Antonie Van Leeuwenhoek       Date:  1992-10       Impact factor: 2.271

3.  In-vitro antifungal susceptibility of clinical and environmental Fusarium spp. strains.

Authors:  I Pujol; J Guarro; J Gené; J Sala
Journal:  J Antimicrob Chemother       Date:  1997-02       Impact factor: 5.790

4.  Paecilomyces varioti fungemia in a bone marrow transplant patient.

Authors:  M M Shing; M Ip; C K Li; K W Chik; P M Yuen
Journal:  Bone Marrow Transplant       Date:  1996-02       Impact factor: 5.483

5.  A bold mold? Paecilomyces variotii peritonitis during continuous ambulatory peritoneal dialysis.

Authors:  R P Eisinger; M P Weinstein
Journal:  Am J Kidney Dis       Date:  1991-11       Impact factor: 8.860

Review 6.  Paecilomyces sinusitis in an immunocompromised adult patient: case report and review.

Authors:  R Gucalp; P Carlisle; P Gialanella; S Mitsudo; J McKitrick; J Dutcher
Journal:  Clin Infect Dis       Date:  1996-08       Impact factor: 9.079

7.  Disseminated hyalohyphomycosis caused by a novel human pathogen, Fusarium napiforme.

Authors:  G P Melcher; D A McGough; A W Fothergill; C Norris; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1993-06       Impact factor: 5.948

8.  Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi.

Authors:  A Espinel-Ingroff; K Dawson; M Pfaller; E Anaissie; B Breslin; D Dixon; A Fothergill; V Paetznick; J Peter; M Rinaldi
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

9.  Comparative study of broth macrodilution and microdilution techniques for in vitro antifungal susceptibility testing of yeasts by using the National Committee for Clinical Laboratory Standards' proposed standard.

Authors:  F Barchiesi; A L Colombo; D A McGough; M G Rinaldi
Journal:  J Clin Microbiol       Date:  1994-10       Impact factor: 5.948

Review 10.  Complicated soft tissue infection with prepatellar bursitis caused by Paecilomyces lilacinus in an immunocompetent host: case report and review.

Authors:  F Westenfeld; W K Alston; W C Winn
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

View more
  29 in total

Review 1.  Developments in fungal taxonomy.

Authors:  J Guarro; A M Stchigel
Journal:  Clin Microbiol Rev       Date:  1999-07       Impact factor: 26.132

2.  Cutaneous hyalohyphomycosis caused by Paecilomyces lilacinus successfully treated by oral voriconazole and nystatin packing.

Authors:  Ching-Yu Huang; Pei-Lun Sun; Hsiang-Kuang Tseng
Journal:  Mycopathologia       Date:  2011-03-20       Impact factor: 2.574

3.  In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.

Authors:  A Espinel-Ingroff
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

4.  Testing of the in vitro susceptibilities of Madurella mycetomatis to six antifungal agents by using the Sensititre system in comparison with a viability-based 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5- [(phenylamino)carbonyl]-2H-tetrazolium hydroxide (XTT) assay and a modified NCCLS method.

Authors:  Wendy W J van de Sande; Ad Luijendijk; Abdalla O A Ahmed; Irma A J M Bakker-Woudenberg; Alex van Belkum
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

5.  Mixed infection caused by two species of Fusarium in a human immunodeficiency virus-positive patient.

Authors:  J Guarro; M Nucci; T Akiti; J Gené
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  Successful treatment of Paecilomyces variotii peritonitis in a liver transplant patient.

Authors:  Meltem Polat; Soner Sertan Kara; Anıl Tapısız; Zeliha Demirtaş; Sinan Sarı; Ayşe Kalkancı; Hasan Tezer; Buket Dalgıç
Journal:  Mycopathologia       Date:  2014-12-23       Impact factor: 2.574

7.  In vitro antifungal activities of the new triazole UR-9825 against clinically important filamentous fungi.

Authors:  J Capilla; M Ortoneda; F J Pastor; J Guarro
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

Review 8.  Challenges in the Polyene- and Azole-Based Pharmacotherapy of Ocular Fungal Infections.

Authors:  Prit Lakhani; Akash Patil; Soumyajit Majumdar
Journal:  J Ocul Pharmacol Ther       Date:  2018-11-08       Impact factor: 2.671

9.  Optimal testing conditions for determining MICs and minimum fungicidal concentrations of new and established antifungal agents for uncommon molds: NCCLS collaborative study.

Authors:  A Espinel-Ingroff; V Chaturvedi; A Fothergill; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

10.  Paecilomyces pyelonephritis in a patient with urolithiasis.

Authors:  K Sriram; Mary S Mathews; Ganesh Gopalakrishnan
Journal:  Indian J Urol       Date:  2007-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.